Results for:

Polymerase: HIV RT

Welcome to the results summary page

This page presents all the results for a polymerase, property or reference. To find more information about a polymerase or reference, follow the relevant link.

Using Polbase tables:

Sorting:

Tables may be sorted by clicking on any of the column titles. A second click reverses the sort order. <Ctrl> + click on the column titles to sort by more than one column (e.g. family then name).

Filtering:

It is also possible to filter the table by typing into the search box above the table. This will instantly hide lines from the table that do not contain your search text.

Help icons:

The show help symbol in the upper-right corner of the page links to this help text. The question mark icon is used everywhere to indicate that help is available.

Polymerase	Reference	Property	Result	Context
HIV RT	Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase.	Processivity	200bp
HIV RT	Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase.	V_max	30 /second	Reaction: Nucleotide incorporation; Substrate: dNTPs
HIV RT	Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase.	K_d	4.7nM	Reaction: Polymerase-DNA interaction; Substrate: DNA template
HIV RT	Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase.	K_d	14uM	Reaction: Nucleotide incorporation; Substrate: dNTPs
HIV RT	The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase.	Reverse Transcriptase Activity	Yes
HIV RT	The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase.	Cloned or native	Cloned in E. coli
HIV RT	The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase.	Full length or truncated	Full length
HIV RT	The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase.	Extension from RNA primer	Yes
HIV RT	Human immunodeficiency virus 1 reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching.	3-5' Exonuclease (proofreading)	No
HIV RT	Human immunodeficiency virus 1 reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching.	5-3' Exonuclease	No
HIV RT	Human immunodeficiency virus 1 reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching.	RNase H	Yes
HIV RT	Human immunodeficiency virus 1 reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching.	Processivity	15bp
HIV RT	Human immunodeficiency virus 1 reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching.	K_M	10uM	Reaction: Nucleotide incorporation; Substrate: dTTP
HIV RT	Human immunodeficiency virus 1 reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching.	K_d	2.3uM	Reaction: Polymerase-DNA interaction; Substrate: RNA-DNA hybrid
HIV RT	Parameters that influence processive synthesis and site-specific termination by human immunodeficiency virus reverse transcriptase on RNA and DNA templates.	Reverse Transcriptase Activity	Yes
HIV RT	Parameters that influence processive synthesis and site-specific termination by human immunodeficiency virus reverse transcriptase on RNA and DNA templates.	Molecular Weight	1.17E+05 Dalton
HIV RT	Parameters that influence processive synthesis and site-specific termination by human immunodeficiency virus reverse transcriptase on RNA and DNA templates.	Full length or truncated	Full length
HIV RT	Parameters that influence processive synthesis and site-specific termination by human immunodeficiency virus reverse transcriptase on RNA and DNA templates.	RNase H	Yes
HIV RT	Parameters that influence processive synthesis and site-specific termination by human immunodeficiency virus reverse transcriptase on RNA and DNA templates.	Processivity	75bp
HIV RT	Parameters that influence processive synthesis and site-specific termination by human immunodeficiency virus reverse transcriptase on RNA and DNA templates.	Specific Activity	2.1E+04 units/mg
HIV RT	Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template.	K_M	10nM	Reaction: Nucleotide incorporation; Substrate: dCTP; Technique: Steady State
HIV RT	Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template.	K_M	40nM	Reaction: Nucleotide incorporation; Substrate: dTTP; Technique: Steady State
HIV RT	Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template.	K_M	20nM	Reaction: Nucleotide incorporation; Substrate: dGTP; Technique: Steady State
HIV RT	Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template.	K_M	100nM	Reaction: Nucleotide incorporation; Substrate: dATP; Technique: Steady State
HIV RT	Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template.	k_cat	0.5 /minute	Reaction: Nucleotide incorporation; Substrate: dCTP; Technique: Steady State
HIV RT	Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template.	k_cat	0.43 /minute	Reaction: Nucleotide incorporation; Substrate: dTTP; Technique: Steady State
HIV RT	Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template.	k_cat	0.12 /minute	Reaction: Nucleotide incorporation; Substrate: dGTP; Technique: Steady State
HIV RT	Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template.	k_cat	0.77 /minute	Reaction: Nucleotide incorporation; Substrate: dATP; Technique: Steady State
HIV RT	Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate.	K_M	0.082uM	Reaction: Nucleotide incorporation; Substrate: dTTP; Technique: Rapid quench (RNA template)
HIV RT	Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate.	K_M	10uM	Reaction: Nucleotide incorporation; Substrate: dNTPs; Technique: Rapid quench (RNA template)
HIV RT	Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate.	K_M	0.19uM	Reaction: Nucleotide incorporation; Substrate: TTP analog; Technique: Rapid quench
HIV RT	Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate.	k_cat	0.025 /second	Reaction: Nucleotide incorporation; Substrate: dTTP; Technique: Rapid quench (RNA template)
HIV RT	Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate.	k_cat	1.9 /second	Reaction: Nucleotide incorporation; Substrate: dNTPs; Technique: Rapid quench (RNA template)
HIV RT	Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate.	k_cat	0.071 /second	Reaction: Nucleotide incorporation; Substrate: TTP analog; Technique: Rapid quench (RNA template)
HIV RT	Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.	Reverse Transcriptase Activity	Yes
HIV RT	N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Reverse Transcriptase Activity	Yes
HIV RT	N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Reverse Transcriptase Activity	Yes
HIV RT	Nucleotide-dependent conformational change governs specificity and analog discrimination by HIV reverse transcriptase.	Reverse Transcriptase Activity	Yes
HIV RT	Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors.	Reverse Transcriptase Activity	Yes
HIV RT	Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors.	RNase H	Yes
HIV RT	Crystal Structure of HIV-1 Reverse Transcriptase Bound to a Non-Nucleoside Inhibitor with a Novel Mechanism of Action.	Reverse Transcriptase Activity	Yes
HIV RT	Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase.	Reverse Transcriptase Activity	Yes
HIV RT	Substituted tetrahydroquinolines as potent allosteric inhibitors of reverse transcriptase and its key mutants.	Reverse Transcriptase Activity	Yes
HIV RT	Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site.	Reverse Transcriptase Activity	Yes
HIV RT	Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site.	RNase H	Yes
HIV RT	HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site.	Reverse Transcriptase Activity	Yes
HIV RT	HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site.	RNase H	Yes
HIV RT	Human immunodeficiency virus type 1 reverse transcriptase: spatial and temporal relationship between the polymerase and RNase H activities.	Reverse Transcriptase Activity	Yes
HIV RT	Human immunodeficiency virus type 1 reverse transcriptase: spatial and temporal relationship between the polymerase and RNase H activities.	Terminal Transferase	Unspecified
HIV RT	Human immunodeficiency virus type 1 reverse transcriptase: spatial and temporal relationship between the polymerase and RNase H activities.	RNase H	Yes
HIV RT	Reverse transcriptase.RNase H from the human immunodeficiency virus. Relationship of the DNA polymerase and RNA hydrolysis activities.	Reverse Transcriptase Activity	Yes
HIV RT	HP 0.35, a cephalosporin degradation product is a specific inhibitor of lentiviral RNAses H.	Reverse Transcriptase Activity	Yes
HIV RT	HP 0.35, a cephalosporin degradation product is a specific inhibitor of lentiviral RNAses H.	RNase H	Yes
HIV RT	Lersivirine: a Non-Nucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus-1.	Reverse Transcriptase Activity	Yes
HIV RT	Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance.	Reverse Transcriptase Activity	Yes
HIV RT	Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Reverse Transcriptase Activity	Yes
HIV RT	Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.	Reverse Transcriptase Activity	Yes
HIV RT	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.	Reverse Transcriptase Activity	Yes
HIV RT	Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.	Reverse Transcriptase Activity	Yes
HIV RT	Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5 -chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.	Reverse Transcriptase Activity	Yes
HIV RT	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.	Reverse Transcriptase Activity	Yes
HIV RT	The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.	Reverse Transcriptase Activity	Yes
HIV RT	High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.	Reverse Transcriptase Activity	Yes
HIV RT	Crystal structures of HIV-1 reverse transcriptase complexes with thiocarbamate non-nucleoside inhibitors.	Reverse Transcriptase Activity	Yes
HIV RT	Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs).	Reverse Transcriptase Activity	Yes
HIV RT	Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design.	Reverse Transcriptase Activity	Yes
HIV RT	3'-Azido-3'-deoxythymidine-(5')-tetraphospho-(5')-adenosine, the product of ATP-mediated excision of chain-terminating AZTMP, is a potent chain-terminating substrate for HIV-1 reverse transcriptase.	Reverse Transcriptase Activity	Yes
HIV RT	The pyrophosphate analogue foscarnet traps the pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase translocation.	Reverse Transcriptase Activity	Yes
HIV RT	HIV-1 reverse transcriptase inhibitors.	Reverse Transcriptase Activity	Yes
HIV RT	Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases.	Reverse Transcriptase Activity	Yes
HIV RT	2'-Deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against all HIV-1 strains, favorable toxic profiles and stability in plasma.	Reverse Transcriptase Activity	Yes
HIV RT	Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action.	Reverse Transcriptase Activity	Yes
HIV RT	Effects of nucleotides and nucleotide analogue inhibitors of HIV-1 reverse transcriptase in a ratchet model of polymerase translocation.	Reverse Transcriptase Activity	Yes
HIV RT	Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.	Reverse Transcriptase Activity	Yes
HIV RT	Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.	Associated condition	HIV
HIV RT	TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.	Reverse Transcriptase Activity	Yes
HIV RT	TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.	Associated condition	HIV
HIV RT	Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates.	Reverse Transcriptase Activity	Yes
HIV RT	Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates.	Associated condition	HIV
HIV RT	Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.	Reverse Transcriptase Activity	Yes
HIV RT	Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.	Associated condition	HIV
HIV RT	Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.	Reverse Transcriptase Activity	Yes
HIV RT	Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.	Associated condition	HIV
HIV RT	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.	Reverse Transcriptase Activity	Yes
HIV RT	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.	Associated condition	HIV
HIV RT	Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.	Reverse Transcriptase Activity	Yes
HIV RT	Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.	Associated condition	HIV
HIV RT	Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase.	Reverse Transcriptase Activity	Yes
HIV RT	Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase.	Associated condition	HIV
HIV RT	Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.	Reverse Transcriptase Activity	Yes
HIV RT	Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.	Associated condition	HIV
HIV RT	Substitutions of Phe61 located in the vicinity of template 5'-overhang influence polymerase fidelity and nucleoside analog sensitivity of HIV-1 reverse transcriptase.	Reverse Transcriptase Activity	Yes
HIV RT	Substitutions of Phe61 located in the vicinity of template 5'-overhang influence polymerase fidelity and nucleoside analog sensitivity of HIV-1 reverse transcriptase.	Associated condition	HIV
HIV RT	Exploring the effects of active site constraints on HIV-1 reverse transcriptase DNA polymerase fidelity.	Reverse Transcriptase Activity	Yes
HIV RT	Exploring the effects of active site constraints on HIV-1 reverse transcriptase DNA polymerase fidelity.	Associated condition	HIV
HIV RT	Study on steady-state kinetics of nucleotide analogues incorporation by non-gel CE.	Reverse Transcriptase Activity	Yes
HIV RT	Comparison of DNA polymerase activities between recombinant feline immunodeficiency and leukemia virus reverse transcriptases.	Molecular Weight	66kD
HIV RT	Comparison of DNA polymerase activities between recombinant feline immunodeficiency and leukemia virus reverse transcriptases.	Overall Error Rate	0.0005 errors/bp
HIV RT	Purification and partial characterization of equine infectious anemia virus reverse transcriptase.	Reverse Transcriptase Activity	Yes
HIV RT	Purification and partial characterization of equine infectious anemia virus reverse transcriptase.	3-5' Exonuclease (proofreading)	No
HIV RT	Purification and partial characterization of equine infectious anemia virus reverse transcriptase.	Nucleotide Substitution Rate	0.003155 errors/bp
HIV RT	Purification and partial characterization of equine infectious anemia virus reverse transcriptase.	Nucleotide Substitution Rate	0.001477 errors/bp
HIV RT	Purification and partial characterization of equine infectious anemia virus reverse transcriptase.	Full length or truncated	Full length
HIV RT	Purification and partial characterization of equine infectious anemia virus reverse transcriptase.	RNase H	Yes
HIV RT	In vitro fidelity of the prototype primate foamy virus (PFV) RT compared to HIV-1 RT.	Frameshift Error Rate	8E-06 errors/bp
HIV RT	In vitro fidelity of the prototype primate foamy virus (PFV) RT compared to HIV-1 RT.	Overall Error Rate	7.5E-05 errors/bp
HIV RT	In vitro fidelity of the prototype primate foamy virus (PFV) RT compared to HIV-1 RT.	Nucleotide Substitution Rate	6.3E-05 errors/bp
HIV RT	In vitro fidelity of the prototype primate foamy virus (PFV) RT compared to HIV-1 RT.	Full length or truncated	Full length
HIV RT	Fidelity of DNA synthesis catalyzed by human DNA polymerase alpha and HIV-1 reverse transcriptase: effect of reaction pH.	3-5' Exonuclease (proofreading)	No
HIV RT	Fidelity of DNA synthesis catalyzed by human DNA polymerase alpha and HIV-1 reverse transcriptase: effect of reaction pH.	Cloned or native	Cloned in E. coli
HIV RT	Fidelity of DNA synthesis catalyzed by human DNA polymerase alpha and HIV-1 reverse transcriptase: effect of reaction pH.	Nucleotide Substitution Rate	2.63E-05 errors/bp	Technique: Reversion (pH 6.5)
HIV RT	Fidelity of DNA synthesis catalyzed by human DNA polymerase alpha and HIV-1 reverse transcriptase: effect of reaction pH.	Nucleotide Substitution Rate	0.00027 errors/bp	Technique: Reversion (pH 8.0)
HIV RT	Fidelity of DNA synthesis catalyzed by human DNA polymerase alpha and HIV-1 reverse transcriptase: effect of reaction pH.	Full length or truncated	Full length
HIV RT	Fidelity of DNA synthesis catalyzed by human DNA polymerase alpha and HIV-1 reverse transcriptase: effect of reaction pH.	Specific Activity	1 umol/min/mg
HIV RT	Mutation Rates and Intrinsic Fidelity of Retroviral Reverse Transcriptases	Frameshift Error Rate	0.00023 errors/bp
HIV RT	Fidelity of the reverse transcriptase of human immunodeficiency virus type 2.	Reverse Transcriptase Activity	Yes
HIV RT	Fidelity of the reverse transcriptase of human immunodeficiency virus type 2.	3-5' Exonuclease (proofreading)	No
HIV RT	Analyzing fidelity of DNA polymerases.	Frameshift Error Rate	0.0047 errors/bp	Technique: Reversion
HIV RT	Analyzing fidelity of DNA polymerases.	Overall Error Rate	0.08 errors/bp	Technique: M13mp2 forward mutation assay
HIV RT	Analyzing fidelity of DNA polymerases.	Overall Error Rate	0.0001 errors/bp	Technique: M13mp2 opal codon reversion assay
HIV RT	Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design.	Reverse Transcriptase Activity	No
HIV RT	Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design.	Associated condition	HIV
HIV RT	Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex.	Reverse Transcriptase Activity	Yes
HIV RT	Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex.	Polymerase Catalytic Residue Amino Acids	D110, D185, D186
HIV RT	Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex.	Incorporation of non-standard nucleotides	Unspecified
HIV RT	Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex.	Cloned or native	Cloned in E. coli
HIV RT	Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex.	Tagged	Yes
HIV RT	Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex.	Tag Name	his
HIV RT	Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex.	Residues Involved in Catalysis of RNase H	D443, E478, D498, D549
HIV RT	Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex.	Full length or truncated	Full length
HIV RT	N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.	Reverse Transcriptase Activity	Yes
HIV RT	N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.	Cloned or native	Cloned in E. coli
HIV RT	N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.	Tagged	Yes
HIV RT	N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.	Tag Name	histidine
HIV RT	N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.	Full length or truncated	Full length
HIV RT	N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.	RNase H	Yes
HIV RT	N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.	Storage requirements	50% glycerol -20oC
HIV RT	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.	Reverse Transcriptase Activity	Yes
HIV RT	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.	Associated condition	HIV